Skip to Main Content

Latest News

Exploring Long-Term Efficacy of Inebilizumab in Phase 3 Myasthenia Gravis Trial: Richard Nowak, MD, MS

Autoreactive B-cells contribute to the onset and progression of generalized myasthenia gravis (gMG) through their role in autoantibody production. Targeting these cells, monoclonal antibody inebilizumab (Uplizna; Amgen), an FDA-approved treatment for neuromyelitis optica spectrum disorder, is currently being investigated in the phase 3 MINT trial (NCT04524273) as a potential therapy for patients with gMG.

Source: HCPLive
Read more
Get RSS Feed